{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-24-002817","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.606206+00:00","generated_at":"2026-05-29T21:01:55.767535+00:00","sec_items":["3.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"TScan converts $15M loan principal into 3.13M shares at $4.785","bullets":["K2 HealthVentures converted $15M of convertible term loan into 3,134,796 voting common shares at $4.785/share.","Shares issued November 20, 2024 under Section 3(a)(9) exemption; no registration statement required.","Conversion reduces debt but dilutes existing stockholders by approximately 5.5% based on shares outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-24-002817","json":"https://secwatch.observer/filing/0000950142-24-002817.json","markdown":"https://secwatch.observer/filing/0000950142-24-002817.md","text":"https://secwatch.observer/filing/0000950142-24-002817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095014224002817/0000950142-24-002817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095014224002817/eh240560212_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T21:01:55.767535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}